Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


123456»
  • ||||||||||  Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Dovato (dolutegravir/lamivudine) / ViiV Healthcare
    Journal:  Antiretroviral therapy in people with HIV and end-stage kidney disease. (Pubmed Central) -  Jan 28, 2025   
    Dual/unboosted ART regimens such as dolutegravir/lamivudine provide robust viral efficacy in the setting of ESKD, and higher than recommended, including full-dose, lamivudine was well tolerated. The dolutegravir/lamivudine (300?mg) fixed-dose combination provides a single-tablet regimen for use across the eGFR spectrum, avoids under-exposure to lamivudine, and merits further evaluation in this population.
  • ||||||||||  Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
    HIV infection in migrant women from sub?Saharan Africa in North East of Italy: a snapshot of a vulnerable population () -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_306;    
    Unstable socio-economic conditions, language barriers and lack of education likely contributed to poor ART adherence. In addition, a significant number of women were diagnosed with HIV after arriving in Italy, underscoring the need for targeted HIV prevention and testing programmes to prevent late HIV diagnoses, which are significantly higher among migrant women in our cohort compared to those in other European countries.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Patient?reported outcomes in switching to long?acting cabotegravir/rilpivirine: a real?life experience () -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_238;    
    In contrast, the stable gut barrier/function and microbial translocation markers suggest no effect of dual cART on gastrointestinal permeability. Thirty-six patients have joined it, via own mobile phone; 11 assigned female at birth (30.5%), with a median age of 47 years (range 29
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Antiretroviral treatment with BIC/FTC/TAF: where we come from and where we are going () -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_237;    
    Antiretroviral therapy with BIC/FTC/TAF is the most commonly used ART in our hospital, being a safe therapy that is generally maintained over time and suitable for PLWH co-infected with HBV. The main reason for discontinuation is the participant's desire to switch to intramuscular therapies.
  • ||||||||||  Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
    Trial completion date, Trial primary completion date:  Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics (clinicaltrials.gov) -  Sep 20, 2024   
    P1/2,  N=20, Recruiting, 
    The observed rates of emergent RAMs at VF were 4% with BIC/FTC/TAF, 8.5% with DTG/ABC/3TC, 18% with DTG/3TC and 39% with DTG/RPV. Trial completion date: Jun 2027 --> May 2028 | Trial primary completion date: Jul 2025 --> Jun 2026
  • ||||||||||  Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
    PNEUMOCYSTIC JIROVECII: ALWAYS A DIFFERENTIAL (Convention Center Exhibit Hall: Poster Area 3) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6439;    
    CASE PRESENTATION: A 52-year-old woman with a history of HIV on antiretroviral therapy (dolutegravir and rilpivirine), previously treated latent tuberculosis, tracheal stenosis and COPD on high dose inhaled fluticasone/salmeterol and tiotropium was evaluated for 3 weeks of progressive dyspnea...Given the acuity of her dyspnea which only partially improved with balloon dilatation, she was treated with oral trimethoprim-sulfamethoxazole for 21 days and ciprofloxacin for 14 days... PJP is an ubiquitous colonizer in the respiratory tract which may become pathogenic and cause clinical pneumonia in the setting of prolonged use of inhaled steroids, especially in HIV patients on protease-inhibitors, even in the setting of immune reconstitution and undetectable viral load.
  • ||||||||||  lamivudine HBV / Generic mfg.
    Complexities of Managing Chronic Hepatitis B in HIV: A Case of Acute Liver Injury Post-Medication Change (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_3544;    
    On further history-taking, she reported a recent change in her HIV medication regimen from Efavirenz/Emtricitabine/Tenofovir to Dolutegravir/Rilpivirine in view of her worsening kidney function...Treatment with Entecavir and Lamivudine was initiated...As in our case, pegylated interferon or nucleos(t)ide analogues can be given to curb liver disease progression in affected individuals. Note: The table for this abstract can be viewed in the ePoster Gallery section of the ACG 2024 ePoster Site or in The American Journal of Gastroenterology's abstract supplement issue, both of which will be available starting October 27, 2024.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    LACTIC ACIDOSIS ASSOCIATED WITH BIKTARVY IN A PATIENT WITH RENAL IMPAIRMENT: A CASE REPORT (Convention Center Exhibit Hall: Poster Area 2) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_5194;    
    This case underscores the significance of closely monitoring individuals with kidney problems who are undergoing TAF-based treatments like Biktarvy for the potential occurrence of lactic acidosis. Detecting it early, discontinuing the medication, and providing appropriate supportive care are all essential steps in managing this potentially life-threatening complication.
  • ||||||||||  Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Vemlidy (tenofovir alafenamide) / Gilead
    Journal:  Development and emerging trends of drug resistance mutations in HIV: a bibliometric analysis based on CiteSpace. (Pubmed Central) -  May 30, 2024   
    Additionally, by choosing medications with a longer half-life, patients can take fewer doses of their prescription, increasing patient compliance. This study involved a bibliometric visualization analysis of the literature on drug resistance mutations, providing insight into the field's evolution and emerging patterns and offering academics a resource to better understand HIV drug resistance mutations and contribute to the field's advancement.
  • ||||||||||  Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
    Study of a randomised switch to DTG/RPV in subjects with HIV RNA <50c/ml and archived K103N (Wisard study): week 96 results (Poster board: 106) -  May 2, 2024 - Abstract #AIDS2024AIDS_1387;    
    The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
  • ||||||||||  Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
    Effectiveness and durability of dolutegravir/rilpivirine in older people with HIV from the Veterans Aging Cohort Study (VACS) (Poster board: 090) -  May 2, 2024 - Abstract #AIDS2024AIDS_1361;    
    The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
  • ||||||||||  Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
    Investigating lipid trends in DOR/RPV/DTG/BIC-including regimens using generalized additive mixed models (Poster board: 088) -  May 2, 2024 - Abstract #AIDS2024AIDS_1284;    
    The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
  • ||||||||||  Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
    Enrollment open, Trial completion date, Trial primary completion date:  Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics (clinicaltrials.gov) -  Mar 28, 2024   
    P1/2,  N=20, Recruiting, 
    In addition, the pill burden was reduced which can add to overall patient satisfaction. Not yet recruiting --> Recruiting | Trial completion date: Jan 2027 --> Jun 2027 | Trial primary completion date: Feb 2025 --> Jul 2025
  • ||||||||||  Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi, Vemlidy (tenofovir alafenamide) / Gilead
    Hepatitis B Reactivation in PLWH With Anti-Core Antibody After Switch to an Anti-HBV Sparing Regimen (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_875;    
    We decided to investigate HBV reactivation in antiHBc-PLWH (with isolated anti-HBc or with anti-HBc and anti-HBsAg) after the switch from ART including drugs active on both viruses (tenofovir disoproxil fumarate, TDF and tenofovir alafenamide, TAF) to an antiHBV sparing regimen (antiHBVsr) because in PLWH the loss of HBsAg with or without anti-HBsAg seroconversion is probably consequent to ART treatment including drugs active on both viruses (HIV/HBV) rather than past HBV infection. Additionally, HBV reactivation has been described in immunocompromised anti-HBsAg positive people.HBV reactivation in antiHBc-PLWH was assessed by an alteration of alanine aminotransferase (ALT) above the upper limit of the normal range after the switch to antiHBVsr dolutegravir/rilpivirine (DOL/RPV) or long acting therapy cabotegravir/rilpivirine (CAB/RPVLA)...The HBV reactivation is unlikely in antiHBc-PLWH with anti-HBsAg positivity after switch to anti-HBVsr, while close monitoring of ALT and possibly HBV-DNA in PLWH with antiHBc alone, after switch to anti-HBVsr is necessary.
  • ||||||||||  Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
    Retrospective data, Journal:  Efficacy and tolerability of dolutegravir/lamivudine versus (Pubmed Central) -  Oct 12, 2023   
    Two study participants experienced virological failure in the DTG/3TC arm. We observed no significant difference in CD4 cell counts, lipid parameters, or renal function between the two groups at 48 weeks.
  • ||||||||||  Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
    Primary HIV Infection in an Adherent Pre-exposure Prophylaxis User with Limited Risk Factors (ePosters) -  Oct 8, 2023 - Abstract #EACS2023EACS_1480;    
    Detection of an NRTI-resistant virus, despite the early infection stage, suggests transmission of an already resistant strain, which jeopardized the efficacy of a PrEP regimen including FTC, especially considering the high adherence. Nevertheless, emergence of resistance driven by PrEP cannot be excluded.
  • ||||||||||  Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
    Primary HIV Infection in an Adherent Pre-exposure Prophylaxis User with Limited Risk Factors (ePosters) -  Oct 8, 2023 - Abstract #EACS2023EACS_1479;    
    Detection of an NRTI-resistant virus, despite the early infection stage, suggests transmission of an already resistant strain, which jeopardized the efficacy of a PrEP regimen including FTC, especially considering the high adherence. Nevertheless, emergence of resistance driven by PrEP cannot be excluded.